Evaxion A/S EVAX 深 滬
已收盤 08-07 16:00:00 美东时间
3.10
+0.105
+3.51%
華盛通- 最 高3.10
- 今 開3.0999
- 成交量 7962股
- 最 低 2.97
- 昨 收 2.995
- 總市值 2585.47万
- 52周最高 12.1499
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.52
- 委 比 13.36%
- 總股本 834.02万
- 歷史最高 1252.00
- 量 比 0.79
- 振 幅 4.34%
- 歷史最低 2.77
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented t...
07-17 19:19
Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion")...
07-01 20:01
Evaxion Unveils Promising Preclinical Data for AI-Designed AML Vaccine EVX-04
Evaxion Biotech ( ($EVAX) ) has issued an announcement. On June 11, 2026, Evaxi...
06-11 18:28
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
Evaxion To Present Preclinical EVX-04 AML Vaccine Data At EHA 2026, Advancing Toward Planned Clinical Trial Submission In 2H 2026
Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel
05-12 21:34
Evaxion Promotes Chief Scientific Officer Birgitte Rono To COO
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on
04-27 20:05
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
04-24 18:32
Evaxion Showcases AI-Immunology Platform's Potential To Develop Glioblastoma Vaccines Using Novel Tumor Targets At AACR
Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a
04-18 03:03
Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01
EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with
04-07 20:10
